{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:12:23Z","timestamp":1793142743034,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/100001916","name":"Williams","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The treatment landscape in relapsed\/refractory chronic lymphocytic leukaemia (CLL) has rapidly evolved over the past five years, with one such emergent treatment being the <jats:italic>BCL2<\/jats:italic> inhibitor, venetoclax. This oral treatment has demonstrated significant clinical advantages in indicated patients, but rapid tumour debulking can lead to a treatment\u2010related risk of the acute condition known as tumour lysis syndrome (TLS). Here, I present real patient cases to show how I have used the recommended predose monitoring and prophylactic procedures to mitigate the risk of TLS. I also used the ramp\u2010up dose escalation schedule of venetoclax therapy initiation to safely take patients through the treatment, successfully providing them with sustained clinical benefits.<\/jats:p>","DOI":"10.1111\/bjh.16345","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T05:40:30Z","timestamp":1576820430000},"page":"844-851","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Practical management of tumour lysis syndrome in venetoclax\u2010treated patients with chronic lymphocytic leukaemia"],"prefix":"10.1111","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8505-7430","authenticated-orcid":false,"given":"John G.","family":"Gribben","sequence":"first","affiliation":[{"name":"Barts Cancer Institute St. Bartholomew's Hospital Queen Mary University of London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08143.x"},{"key":"e_1_2_10_3_1","unstructured":"Cancer Research UK(2019)A trial of ibrutinib with rituximab for chronic lymphocytic leukaemia (FLAIR). Available athttps:\/\/www.cancerresearchuk.org\/about-cancer\/find-a-clinical-trial\/a-trial-ibrutinib-rituximab-chronic-lymphocytic-leukaemia-flair. Last accessed March 2019."},{"key":"e_1_2_10_4_1","unstructured":"ClinicalTrials.gov: NCT02910583(2019) Available athttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02910583. Last accessed March 2019."},{"key":"e_1_2_10_5_1","unstructured":"ClinicalTrials.gov: NCT03513562(2019) Available athttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03513562. Last accessed March 2019."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.10.861"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0177"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788133"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv303"},{"key":"e_1_2_10_11_1","unstructured":"ESMO(2017)Clinical Guidelines. eUpdate \u2013 Chronic Lymphocytic Leukaemia Treatment Recommendations UK. Available athttps:\/\/www.esmo.org\/Guidelines\/Haematological-Malignancies\/Chronic-Lymphocytic-Leukaemia\/eUpdate-Treatment-Recommendations. Last accessed March 2019."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-01-896290"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-182"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13403"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01580"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0955"},{"key":"e_1_2_10_19_1","volume-title":"Hematopoietic and Lymphoid Neoplasm Database: Chronic Lymphocytic Leukemia\/small lymphocytic lymphoma","author":"SEER","year":"2019"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30012-8"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"e_1_2_10_23_1","unstructured":"Venetoclax [Summary of Product Characteristics](2018)AbbVie Ltd December 2018."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7502"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16345","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16345","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16345","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T21:11:14Z","timestamp":1694034674000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,19]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/bjh.16345"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16345","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,19]]},"assertion":[{"value":"2019-12-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}